Article

Castanotto D, Rossi JJThe promises and pitfalls of RNA-interference-based therapeutics. Nature 457:426-433

Department of Molecular Biology and City of Hope Graduate School of Biological Sciences, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA.
Nature (Impact Factor: 42.35). 02/2009; 457(7228):426-33. DOI: 10.1038/nature07758
Source: PubMed

ABSTRACT The discovery that gene expression can be controlled by the Watson-Crick base-pairing of small RNAs with messenger RNAs containing complementary sequence - a process known as RNA interference - has markedly advanced our understanding of eukaryotic gene regulation and function. The ability of short RNA sequences to modulate gene expression has provided a powerful tool with which to study gene function and is set to revolutionize the treatment of disease. Remarkably, despite being just one decade from its discovery, the phenomenon is already being used therapeutically in human clinical trials, and biotechnology companies that focus on RNA-interference-based therapeutics are already publicly traded.

Download full-text

Full-text

Available from: John J Rossi, Jun 22, 2015
0 Followers
 · 
153 Views
  • Source
    • "RNA interference (RNAi) has been proven to be a useful approach to treat various genetic diseases. It can down-regulate specific protein expression by silencing the activity of its targeted gene [1] [2] [3] [4] [5]. This approach exhibits significant promises for the development of a new class of molecular therapeutic drugs that interferes with disease-causing or –promoting genes, particularly those that encode the so-called ''non-druggable'' targets not amenable to conventional therapeutics [6] [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: RNA interference (RNAi) mediated gene silencing holds significant promises in gene therapy. A major obstacle to efficient RNAi is the systemic delivery of the therapeutic RNAs into the cytoplasmon whithout being trapped in intracellular endo-/lyso-somes. Herein we report the development of a PEGylated, RGD peptide modified, and disulfide cross-linked short polyethylenimines (DSPEIs)functionalized gold nanorod (RDG) for targeted small hairpin (sh)RNA delivery. The RDG effectively condensed shRNAs into stable nanoparticles, allowing for highly specific targeting of model human brain cancer cells (U-87 MG-GFP)viathe αvβ3integrins-mediated endocytosis. The combined effects of endosomal escape (viathe proton-sponge effect of the PEIs)and efficient cleavage of the disulfide-cross-linked DSPEIsby the high intracellular glutathione content triggered rapid cytoplasma shRNAs release resulted in excellent RNAi efficiency and low cytotoxicity. Furthermore, the high stability and prolonged blood circulation afforded by PEGylation allowed for highly effective, targeted tumor accumulation and internalization of the carriers, resulting in outstanding intra-tumor gene silencing efficiency in U-87 MG-GFP tumor bearing BALB/c mice. Combining the capabilities of both passive and active targeting, intracellular glutathione-triggered "off-on" release and endosomal escape, the RDG nanocarrier developed herein appears to be a highly promising non-viral vector for efficient RNAi. Copyright © 2015. Published by Elsevier Ltd.
    Acta biomaterialia 05/2015; DOI:10.1016/j.actbio.2015.05.028 · 5.68 Impact Factor
  • Source
    • "The importance and applications of transition metal–ligand complexes are widespread from synthetic chemistry to material science and biochemistry. These metals have been used for drug design and delivery [12] [13] [14] [15] [16] [17], catalysis [18] [19] [20] [21], solar cell applications [22] [23] [24], and biological imaging [25] [26]. In biological systems , transition metals are involved with very specific structural and cellular functions. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Some transition metal complexes of phenylalanine of general formula [M(C9H10NO2)2]; where M=Mn(II), Co(II), Ni(II), Cu(II) and Zn(II) are prepared in aqueous medium and characterized by spectroscopic, thermo-gravimetric (TG) and magnetic susceptibility analysis. Density functional theory (DFT) has been employed calculating the equilibrium geometries and vibrational frequencies of those complexes at B3LYP level of theory using 6-31G(d) and SDD basis sets. In addition, frontier molecular orbital and time-dependent density functional theory (TD-DFT) calculations are performed with CAM-B3LYP/6-31+G(d,p) and B3LYP/SDD level of theories. Thermo-gravimetric analysis confirms the composition of the complexes by comparing the experimental and calculated data for C, H, N and metals. Experimental and computed IR results predict a significant change in vibrational frequencies of metal-phenylalanine complexes compared to free ligand. DFT calculation confirms that Mn, Co, Ni and Cu complexes form square planar structure whereas Zn adopts distorted tetrahedral geometry. The metal-oxygen bonds in the optimized geometry of all complexes are shorter compared to the metal-nitrogen bonds which is consistent with a previous study. Cation-binding energy, enthalpy and Gibbs free energy indicates that these complexes are thermodynamically stable. UV-vis and TD-DFT studies reveal that these complexes demonstrate representative metal-to-ligand charge transfer (MLCT) and d-d transitions bands. TG analysis and IR spectra of the metal complexes strongly support the absence of water in crystallization. Magnetic susceptibility data of the complexes exhibits that all except Zn(II) complex are high spin paramagnetic. Copyright © 2014 Elsevier B.V. All rights reserved.
    Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy 11/2014; 138:499-508. DOI:10.1016/j.saa.2014.11.084 · 2.13 Impact Factor
  • Source
    • "Traditional chemotherapeutic drugs indiscriminately target and destroy both malignant and healthy cells, resulting in severe side effects [1]. Therapeutics, such as monoclonal antibodies and small interfering RNA (siRNA), are well suited to target tumor cells or specific genes but are associated with an increased risk of adverse immune reactions [2] [3] and ineffective delivery to cells [4]. New treatments based on the targeted delivery of therapeutic agents to the tumor microenvironment [5] rely on nanoparticles (NP) able encapsulate poorly soluble drugs [6], to provide protection from degradation [7], to enhance cellular internalization [8], or to trigger the release of payloads based on environmental cues [9]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nanovectors are a viable solution to the formulation of poorly soluble anticancer drugs. Their bioaccumulation in the tumor parenchyma is mainly achieved exploiting the enhanced permeability and retention (EPR) effect of the leaky neovasculature. In this paper we demonstrate that multistage nanovectors (MSV) exhibit rapid tumoritropic homing independent of EPR, relying on particle geometry and surface adhesion. By studying endothelial cells overexpressing vascular endothelial growth factor receptor-2 (VEGFR2), we developed MSV able to preferentially target VEGFR2 expressing tumor-associated vessels. Static and dynamic targeting revealed that MSV conjugated with anti-VEGFR2 antibodies displayed greater than a 4-fold increase in targeting efficiency towards VEGFR2 expressing cells while exhibiting minimal adherence to control cells. Additionally, VEGFR2 conjugation bestowed MSV with a significant increase in breast tumor targeting and in the delivery of a model payload while decreasing their accumulation in the liver. Surface functionalization with an anti-VEGFR2 antibody provided enhanced affinity towards the tumor vascular endothelium, which promoted enhanced adhesion and tumoritropic accumulation of a reporter molecule released by the MSV.
    Biomaterials 08/2014; 35(37). DOI:10.1016/j.biomaterials.2014.08.024 · 8.31 Impact Factor
Show more